Reading a durability list through its own control experiment, testing longevity claims against the legal history, and separating an irreplaceable asset from a merely expensive one.
How to read this page: Part II applies the same screen as
Part I, so the methods below are the ones this half adds — chiefly the discipline the conclusion introduces, and the pharmaceutical pair the issue accidentally sets up as a controlled comparison. Written post, so no timestamps.
1. Look for the control pair inside any thematic list, and let it size the theme's actual power
The repeatable method
- Scan the list for two names in the same industry, of similar age, given nearly the same argument.
- Compare their realised returns over the same window. Any gap is the part the theme does not explain.
- Attribute that residual explicitly — capital allocation, pipeline productivity, the starting valuation — and ask which of those you can actually assess in advance.
- Downgrade the theme from a reason to buy to a reason to look, in proportion to the size of the gap.
Here: LLY (founded 1876) and PFE (founded 1849) get near-identical durability arguments — permanent demand, decades of research, patent protection. Realised: Lilly "more than 17,000% since 1990"; Pfizer "9.8% per year on average since 1990." Both survived; only one compounded. BF.B at 8.5% a year against SHW at 15.5% makes the same point across consumer and industrial.
Watch for
- Lists that avoid publishing per-name returns, which removes the ability to run this test at all.
- Your own tendency to remember the 17,000% and forget the 9.8% from the same page.
2. Verify a longevity claim against the corporate lineage, not the founding anecdote
The repeatable method
- For any "founded in 18xx" claim, find out what the entity you would actually buy today is, legally and operationally.
- Note mergers, spin-offs, bankruptcies and renamings. Each one breaks continuity in a different way and only some of them matter.
- Ask what actually persisted through the break — the customers, the network, the licence, the brand — and treat that, not the date, as the durable asset.
- Separate the founding date from the listing date: a business that was private for a century has an unobserved record.
Here: CL is dated to William Colgate's 1806 shop, but the post itself notes "the modern company comes from a 1928 merger with Palmolive (founded 1898)." MCO in Part I is dated 1909 but "spun off as we know it today in 2000." AXP was founded in 1850 as a freight company — nothing about the 1850 business survives except the name and, arguably, the habit of moving valuables reliably.
Watch for
- Founding dates that belong to an acquired predecessor rather than the listed parent.
- Long private histories: the founding-to-IPO gaps here run from 24 years (Sherwin-Williams was public within a century) to 124 (Colgate) — the unobserved period tells you nothing about shareholder outcomes.
3. Distinguish an asset that cannot be rebuilt from one that is merely expensive to rebuild
The repeatable method
- Ask the question directly: with unlimited capital, could a competitor recreate this asset today?
- If the barrier is money, it is a cost advantage and it erodes when capital is cheap or when a rival is subsidised.
- If the barrier is legal, geographic or political — a right of way, a licence, a planning regime, an accumulated trust position — it is genuinely irreplaceable and deserves a longer forecast horizon.
- Rank the candidates by which kind of barrier they have, and be sceptical of any moat described only as "scale."
Here: UNP is the clean case — a network "almost impossible to build today," originating in a Congressional charter under the 1862 Pacific Railway Act; the land could not be assembled now at any price. SHW's owned-store network and DE's dealer network are the intermediate case: buildable in principle, but only after years of losses and with no customers in the meantime.
Watch for
- Technological bypass rather than direct replication — nobody will lay parallel track, but freight can move by road or by pipeline.
- Regulated irreplaceable assets attracting regulated returns, which caps the upside the moat appears to promise.
4. Use purchase frequency and unit size as a forecastability test
The repeatable method
- For a consumer business, characterise the typical purchase: how small, how frequent, how habitual, how deferrable.
- Small, frequent, habitual and non-deferrable purchases produce revenue that survives recessions almost unchanged — which is what makes long-horizon cash-flow forecasts defensible at all.
- Test the opposite direction too: can the customer trade down to a cheaper substitute without effort? Habit is only a moat while switching feels like a decision.
- Prefer this test to brand-strength language, which is unfalsifiable.
Here: CL states it outright — "Everyday, repeated purchases create steady, predictable cash flow." The same structure carries PG ("everyday household products"), KO and, more weakly, BF.B, whose 8.5% annual return suggests habit alone does not produce a good investment.
Watch for
- Private-label substitution in exactly these categories — the habit belongs to the product, not always to the brand.
- Categories where a drug, a regulation or a fashion changes the underlying behaviour, which is the one thing this test assumes cannot happen.
5. Publish the caveat with the list, in the same document
The repeatable method
- When you produce a screen output, state explicitly what the screen does and does not claim.
- Say whether a price has been considered. If none has, say so — a list of businesses is not a list of investments.
- Give the reader the intended use: idea generation, watch list, or action.
- Keep the caveat in the same document as the names, because the names travel and the caveat does not.
Here: "None of these companies are guaranteed to outperform the market. But they've already passed the test of time… That's exactly why you might find some great investment ideas in this list." That is a correctly scoped claim, and it is the sentence Part I was missing. No valuation, multiple or expected return appears anywhere in either half.
Watch for
- The caveat appearing only at the end, after ten enthusiastic entries — placement determines whether it is read.
- Screens circulated as recommendations once the framing is stripped away, which is what happens to every list of tickers eventually.
Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.